MediWound Ltd. (MDWD) |
|
9.67 0.3 (3.2%)
|
06-06 15:59 |
|
Open: |
9.8 |
Pre. Close: |
9.37 |
|
High:
|
9.88 |
Low:
|
9.28 |
|
Volume:
|
11,570 |
Market Cap:
|
92(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:50:38 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 12.23  One year: 13.46 |
| Support: |
Support1: 8.76 Support2: 7.28 |
| Resistance: |
Resistance1: 10.47 Resistance2: 11.52 |
| Pivot: |
9.55 |
| Moving Average: |
MA(5): 9.17 MA(20): 9.77
MA(100): 11.9 MA(250): 11.63 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 26 %D(3): 18.4 |
| RSI: |
RSI(14): 40.1 |
| 52-week: |
High: 15.72 Low: 8.05 |
| Average Vol(K): |
3-Month: 19 (K) 10-Days: 23 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MDWD ] has closed above bottom band by 49.8%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.38 - 9.42 |
9.42 - 9.46 |
|
Low:
|
8.71 - 8.75 |
8.75 - 8.79 |
|
Close:
|
9.18 - 9.25 |
9.25 - 9.31 |
|
Company Description |
|
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. |
Headline News |
Tue, 30 May 2023
MediWound Ltd. Down 4.99% To $9.23 After Earnings Miss - InvestorsObserver
Tue, 30 May 2023
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research
Tue, 30 May 2023
MediWound: Q1 Earnings Snapshot - Chron
Tue, 30 May 2023
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update - Yahoo Finance
Fri, 12 May 2023
MediWound to Report First Quarter 2023 Financial Results - GlobeNewswire
Thu, 16 Mar 2023
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
9 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
24.2 (%) |
|
% Held by Institutions
|
26.3 (%) |
|
Shares Short
|
57 (K) |
|
Shares Short P.Month
|
68 (K) |
Stock Financials |
|
EPS
|
-3.48 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.5 |
|
Profit Margin (%)
|
-74 |
|
Operating Margin (%)
|
-28.2 |
|
Return on Assets (ttm)
|
-13.4 |
|
Return on Equity (ttm)
|
-619.1 |
|
Qtrly Rev. Growth
|
111.6 |
|
Gross Profit (p.s.)
|
1.38 |
|
Sales Per Share
|
2.79 |
|
EBITDA (p.s.)
|
-0.71 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
-2.76 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
6.32 |
|
Price to Sales
|
3.41 |
|
Price to Cash Flow
|
-7.62 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
